Summit Therapeutics Inc.
SMMT
$16.35
$0.231.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 77.63M | 103.12M | 360.42M | 15.59M | 14.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 224.93M | 234.21M | 568.44M | 66.85M | 65.61M |
| Operating Income | -224.93M | -234.21M | -568.44M | -66.85M | -65.61M |
| Income Before Tax | -219.17M | -231.79M | -565.71M | -62.91M | -61.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -219.17M | -231.79M | -565.71M | -62.91M | -61.20M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -219.17M | -231.79M | -565.71M | -62.91M | -61.20M |
| EBIT | -224.93M | -234.21M | -568.44M | -66.85M | -65.61M |
| EBITDA | -224.88M | -234.17M | -568.40M | -66.83M | -65.59M |
| EPS Basic | -0.29 | -0.31 | -0.76 | -0.09 | -0.08 |
| Normalized Basic EPS | -0.18 | -0.19 | -0.48 | -0.05 | -0.05 |
| EPS Diluted | -0.29 | -0.31 | -0.76 | -0.09 | -0.09 |
| Normalized Diluted EPS | -0.18 | -0.19 | -0.48 | -0.05 | -0.05 |
| Average Basic Shares Outstanding | 766.64M | 743.42M | 742.62M | 738.08M | 737.50M |
| Average Diluted Shares Outstanding | 766.64M | 743.42M | 742.62M | 738.08M | 737.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |